CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
EQS via SeaPRwire.com / 12/06/2026 / 15:02 UTC+8 Shanghai – 12 Jun 2026 – The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone
More